drugset / Trial / NCT00471081

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081

Phase 2 Completed 385 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.

Timeline

Start
2007-07-05
Primary completion
2008-10-23
Completion
2008-11-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK134612 Vaccine Intramuscular